Rohto Pharmaceutical, headquartered in Osaka, announced that it will acquire Singapore's herbal medicine manufacturer, the largest in Southeast Asia, along with a major trading company for approximately 88 billion yen. The aim is to strengthen business in the health field.
According to an announcement, Rohto Pharmaceutical, along with Mitsui & Co., a major trading company, will acquire 86% of the shares in the local herbal medicine maker "Yuyansan" through a company established in Singapore at the end of June this year from a company related to the founder's family. and acquire it.
The acquisition price is said to be approximately 88 billion yen in Japanese yen, with Rohto Pharmaceutical ultimately holding approximately 60% of the shares and Mitsui & Co. approximately 30%.
Founded in 1879, Yu Yansan is a manufacturer of Chinese herbal medicines and foods, and is known as the largest company in Southeast Asia in the field of Chinese medicine, with over 170 stores in Singapore, Malaysia, Hong Kong, and other countries.
Rohto Pharmaceutical aims to strengthen its business in the health field, including disease prevention, by combining the acquired company's brand power in Asia with its own R&D strengths.
Chairman Kunio Yamada said at a press conference, ``As the population continues to age in Asia, prevention will become more important than ever.'' I think now is the time to integrate products."